Clinical Trial: To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

U.S., July 7 -- ClinicalTrials.gov registry received information related to the study (NCT07684820) titled 'To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment' on May 06.

Brief Summary: This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD. Study participants will be randomized to receive either study drug or placebo administered once daily for 52 weeks.

Study Start Date: June 30

Study Type: INTERVENTIONAL

Condition: Chronic Obstructive Pulmonary Disease (COPD)

Intervention: DRUG: EXPD-101/FXS7553 Dose 1

Oral tablet

DRUG: EXPD-101/FXS7553 Dose 2

Oral tablet

DRUG: Placebo

EXPD-101/FXS7553 ...